Apogee Therapeutics, Inc.
HealthcareNASDAQ:APGE · NASDAQ Global Market
-$1.17 today
Vol 0.98M · Avg 0.96M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-28.3%
avg -26.0%
ROIC
-31.3%
avg -26.8%
ROA
-27.3%
avg -24.6%
Analysis
ROA is currently the strongest return metric at -27.3% versus its period average of -24.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Michael Thomas Henderson | Chief Executive Officer & Director | $1.29M | — | 36 | $1.12M | 1.80% |
Jane Pritchett V. Henderson | Chief Financial Officer | $855,900.00 | — | 60 | $1.12M | 1.80% |
Carl Linden Dambkowski | Chief Medical Officer | $855,900.00 | — | 41 | $211,148.00 | 0.34% |
Rebecca Dabora | Chief Development Officer | — | — | 66 | — | — |
Noel Kurdi | Vice President of Investor Relations | — | — | — | — | — |
Wendy Aspden-Curran | Senior Vice President of Clinical Operations | — | — | — | — | — |
Mehrak Kiankarimi | Senior Vice President of Program & Portfolio | — | — | — | — | — |
Dan Mulreany | Chief Business Officer | — | — | — | — | — |
Monica Forbes | Senior Vice President of Finance | — | — | 50 | — | — |
Matthew Batters | Chief Legal Officer & Corporate Secretary | — | — | 50 | — | — |
Emily Cox | SVP & Head of People | — | — | — | — | — |
Drew Badger | Senior Vice President and Head of Regulatory Affairs & Toxicology | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$0.00
Sells
78
$154.91M
Net Sentiment
$154.91M
Net selling
Most Active
Dambkowski Carl
30 transactions
1–10 of 79
Analysis
Insiders reported 1 buys worth $0.00 and 78 sells worth $154.91M over the last 12 months. That adds up to net selling of $154.91M. Dambkowski Carl was the most active insider with 30 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A5 analysts |
| Revenue | N/A | N/A | N/A | N/A6 analysts |
| Net Income | N/A | N/A | N/A | N/A6 analysts |
| EBIT | N/A | N/A | N/A | N/A6 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Peer companies in the same sector
Legend Biotech Corporation
NASDAQ:LEGN
$6.72B
Centessa Pharmaceuticals plc
NASDAQ:CNTA
$6.14B
CG Oncology, Inc. Common stock
NASDAQ:CGON
$5.28B
Celcuity Inc.
NASDAQ:CELC
$4.32B
Xenon Pharmaceuticals Inc.
NASDAQ:XENE
$4.12B
Soleno Therapeutics, Inc.
SLNO
$2.76B
Disc Medicine, Inc.
NASDAQ:IRON
$2.60B
Ultragenyx Pharmaceutical Inc.
NASDAQ:RARE
$2.40B
Zai Lab Limited
NASDAQ:ZLAB
$1.93B
Ascentage Pharma Group International
NASDAQ:AAPG
$411.36M
Who manages APGE?
Apogee Therapeutics, Inc. (APGE) lists 12 active executives. The top listed executive is Jane Pritchett V. Henderson, Chief Financial Officer.
Are APGE insiders buying or selling?
Recent insider activity shows net selling of $36.17M.
Explore More
Continue the stock analysis
Jump to another research area for this company.